Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $5.8 million.

  • Dianthus Therapeutics' Share-based Compensation rose 50.89% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 113.70%. This contributed to the annual value of $12.9 million for FY2024, which is 344.62% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Share-based Compensation stood at $5.8 million, which was up 1.54% from $5.7 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Share-based Compensation ranged from a high of $5.8 million in Q3 2025 and a low of $462,000 during Q2 2023.
  • Its 3-year average for Share-based Compensation is $3.0 million, with a median of $3.1 million in 2024.
  • As far as peak fluctuations go, Dianthus Therapeutics' Share-based Compensation tumbled by 74.96% in 2023, and later skyrocketed by 571.21% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Share-based Compensation (Quarterly) stood at $513,000 in 2022, then skyrocketed by 41.52% to $726,000 in 2023, then surged by 439.67% to $3.9 million in 2024, then surged by 50.89% to $5.8 million in 2025.
  • Its Share-based Compensation was $5.8 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.3 million in Q1 2025.